Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2013 2
2014 4
2015 4
2016 2
2017 1
2018 3
2019 1
2020 7
2021 8
2022 5
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH; ESCORT-1st Investigators. Luo H, et al. JAMA. 2021 Sep 14;326(10):916-925. doi: 10.1001/jama.2021.12836. JAMA. 2021. PMID: 34519801 Free PMC article. Clinical Trial.
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J; ESCORT Study Group. Huang J, et al. Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13. Lancet Oncol. 2020. PMID: 32416073 Clinical Trial.
Leading causes of castration-resistant prostate cancer.
Lu M, Lu H, Kong Q. Lu M, et al. Among authors: lu h. Expert Rev Anticancer Ther. 2015 Apr;15(4):425-32. doi: 10.1586/14737140.2015.1007957. Epub 2015 Feb 3. Expert Rev Anticancer Ther. 2015. PMID: 25645203 Review.
A Non-Newtonian liquid metal enabled enhanced electrography.
Timosina V, Cole T, Lu H, Shu J, Zhou X, Zhang C, Guo J, Kavehei O, Tang SY. Timosina V, et al. Among authors: lu h. Biosens Bioelectron. 2023 Sep 1;235:115414. doi: 10.1016/j.bios.2023.115414. Epub 2023 May 20. Biosens Bioelectron. 2023. PMID: 37236012 Free article.
48 results